Comparison of radiochemotherapy alone to surgery plus radio(chemo)therapy for non-metastatic stage III/IV squamous cell carcinoma of the head and neck

A matched-pair analysis

Dirk Rades, Thekla Meyners, Nadja Kazic, Amira Bajrovic, Volker Rudat, Steven E. Schild

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background and Purpose: The standard treatment for non-metastatic stage III/IV squamous cell carcinoma of the head and neck varies worldwide. This study compared the outcomes of radiochemotherapy alone to surgery followed by radio(chemo)therapy (radiotherapy plus/minus concurrent chemotherapy). Patients and Methods: Data from 148 patients treated with radiochemotherapy alone were matched to 148 patients treated with surgery plus radio(chemo)therapy. Groups were matched 1:1 for nine potential prognostic factors including age, gender, performance status, tumor site, histologic grade, T category, N category, AJCC stage, and hemoglobin level before radiotherapy, and compared for locoregional control, metastases-free survival, and overall survival. Results: Locoregional control rates at 1, 2, and 3 years were 81%, 73%, and 67% after surgery plus radio(chemo)therapy and 81%, 74%, and 65% after radiochemotherapy alone (p = 0.89). Metastases-free survival rates were 86%, 80%, and 75% after surgery plus radio(chemotherapy) versus 87%, 80%, and 72% after radiochemotherapy alone (p = 0.57). Overall survival rates were 80%, 64%, and 63% after surgery plus radio(chemo)therapy versus 83%, 68%, and 60% after radiochemotherapy alone (p = 0.96). On multivariate analyses, T category (p < 0.001), N category (p = 0.004), and hemoglobin level prior to radiotherapy (p < 0.001) were associated with locoregional control. Histologic grade (p = 0.045), T category (p < 0.001), N category (p = 0.003), and hemoglobin level prior to radiotherapy (p < 0.001) were associated with metastases-free survival. Histologic grade (p = 0.030), ECOG performance status (p = 0.033), T category (p = 0.007), N category (p = 0.024) and hemoglobin level before radiotherapy (p < 0.001) were associated with overall survival. Conclusion: Outcomes of radiochemotherapy alone appeared similar to those of surgery plus radio(chemo)therapy. Randomized trials comparing both treatments for different tumor sites are warranted.

Original languageEnglish (US)
Pages (from-to)541-547
Number of pages7
JournalStrahlentherapie und Onkologie
Volume187
Issue number9
DOIs
StatePublished - Sep 2011

Fingerprint

Matched-Pair Analysis
Chemoradiotherapy
Radiotherapy
Drug Therapy
Hemoglobins
Neoplasm Metastasis
Survival
Survival Rate
Carcinoma, squamous cell of head and neck
Radio
Neoplasms
Research Design
Multivariate Analysis
Outcome Assessment (Health Care)

Keywords

  • Head-and-neck cancer
  • Radiochemotherapy
  • Surgery

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Oncology

Cite this

Comparison of radiochemotherapy alone to surgery plus radio(chemo)therapy for non-metastatic stage III/IV squamous cell carcinoma of the head and neck : A matched-pair analysis. / Rades, Dirk; Meyners, Thekla; Kazic, Nadja; Bajrovic, Amira; Rudat, Volker; Schild, Steven E.

In: Strahlentherapie und Onkologie, Vol. 187, No. 9, 09.2011, p. 541-547.

Research output: Contribution to journalArticle

Rades, Dirk ; Meyners, Thekla ; Kazic, Nadja ; Bajrovic, Amira ; Rudat, Volker ; Schild, Steven E. / Comparison of radiochemotherapy alone to surgery plus radio(chemo)therapy for non-metastatic stage III/IV squamous cell carcinoma of the head and neck : A matched-pair analysis. In: Strahlentherapie und Onkologie. 2011 ; Vol. 187, No. 9. pp. 541-547.
@article{b6d85d8d740a4bf9ab1d8c57ed43ade3,
title = "Comparison of radiochemotherapy alone to surgery plus radio(chemo)therapy for non-metastatic stage III/IV squamous cell carcinoma of the head and neck: A matched-pair analysis",
abstract = "Background and Purpose: The standard treatment for non-metastatic stage III/IV squamous cell carcinoma of the head and neck varies worldwide. This study compared the outcomes of radiochemotherapy alone to surgery followed by radio(chemo)therapy (radiotherapy plus/minus concurrent chemotherapy). Patients and Methods: Data from 148 patients treated with radiochemotherapy alone were matched to 148 patients treated with surgery plus radio(chemo)therapy. Groups were matched 1:1 for nine potential prognostic factors including age, gender, performance status, tumor site, histologic grade, T category, N category, AJCC stage, and hemoglobin level before radiotherapy, and compared for locoregional control, metastases-free survival, and overall survival. Results: Locoregional control rates at 1, 2, and 3 years were 81{\%}, 73{\%}, and 67{\%} after surgery plus radio(chemo)therapy and 81{\%}, 74{\%}, and 65{\%} after radiochemotherapy alone (p = 0.89). Metastases-free survival rates were 86{\%}, 80{\%}, and 75{\%} after surgery plus radio(chemotherapy) versus 87{\%}, 80{\%}, and 72{\%} after radiochemotherapy alone (p = 0.57). Overall survival rates were 80{\%}, 64{\%}, and 63{\%} after surgery plus radio(chemo)therapy versus 83{\%}, 68{\%}, and 60{\%} after radiochemotherapy alone (p = 0.96). On multivariate analyses, T category (p < 0.001), N category (p = 0.004), and hemoglobin level prior to radiotherapy (p < 0.001) were associated with locoregional control. Histologic grade (p = 0.045), T category (p < 0.001), N category (p = 0.003), and hemoglobin level prior to radiotherapy (p < 0.001) were associated with metastases-free survival. Histologic grade (p = 0.030), ECOG performance status (p = 0.033), T category (p = 0.007), N category (p = 0.024) and hemoglobin level before radiotherapy (p < 0.001) were associated with overall survival. Conclusion: Outcomes of radiochemotherapy alone appeared similar to those of surgery plus radio(chemo)therapy. Randomized trials comparing both treatments for different tumor sites are warranted.",
keywords = "Head-and-neck cancer, Radiochemotherapy, Surgery",
author = "Dirk Rades and Thekla Meyners and Nadja Kazic and Amira Bajrovic and Volker Rudat and Schild, {Steven E.}",
year = "2011",
month = "9",
doi = "10.1007/s00066-011-2262-2",
language = "English (US)",
volume = "187",
pages = "541--547",
journal = "Strahlentherapie und Onkologie : Organ der Deutschen R{\"o}ntgengesellschaft ... [et al]",
issn = "0179-7158",
publisher = "Urban und Vogel",
number = "9",

}

TY - JOUR

T1 - Comparison of radiochemotherapy alone to surgery plus radio(chemo)therapy for non-metastatic stage III/IV squamous cell carcinoma of the head and neck

T2 - A matched-pair analysis

AU - Rades, Dirk

AU - Meyners, Thekla

AU - Kazic, Nadja

AU - Bajrovic, Amira

AU - Rudat, Volker

AU - Schild, Steven E.

PY - 2011/9

Y1 - 2011/9

N2 - Background and Purpose: The standard treatment for non-metastatic stage III/IV squamous cell carcinoma of the head and neck varies worldwide. This study compared the outcomes of radiochemotherapy alone to surgery followed by radio(chemo)therapy (radiotherapy plus/minus concurrent chemotherapy). Patients and Methods: Data from 148 patients treated with radiochemotherapy alone were matched to 148 patients treated with surgery plus radio(chemo)therapy. Groups were matched 1:1 for nine potential prognostic factors including age, gender, performance status, tumor site, histologic grade, T category, N category, AJCC stage, and hemoglobin level before radiotherapy, and compared for locoregional control, metastases-free survival, and overall survival. Results: Locoregional control rates at 1, 2, and 3 years were 81%, 73%, and 67% after surgery plus radio(chemo)therapy and 81%, 74%, and 65% after radiochemotherapy alone (p = 0.89). Metastases-free survival rates were 86%, 80%, and 75% after surgery plus radio(chemotherapy) versus 87%, 80%, and 72% after radiochemotherapy alone (p = 0.57). Overall survival rates were 80%, 64%, and 63% after surgery plus radio(chemo)therapy versus 83%, 68%, and 60% after radiochemotherapy alone (p = 0.96). On multivariate analyses, T category (p < 0.001), N category (p = 0.004), and hemoglobin level prior to radiotherapy (p < 0.001) were associated with locoregional control. Histologic grade (p = 0.045), T category (p < 0.001), N category (p = 0.003), and hemoglobin level prior to radiotherapy (p < 0.001) were associated with metastases-free survival. Histologic grade (p = 0.030), ECOG performance status (p = 0.033), T category (p = 0.007), N category (p = 0.024) and hemoglobin level before radiotherapy (p < 0.001) were associated with overall survival. Conclusion: Outcomes of radiochemotherapy alone appeared similar to those of surgery plus radio(chemo)therapy. Randomized trials comparing both treatments for different tumor sites are warranted.

AB - Background and Purpose: The standard treatment for non-metastatic stage III/IV squamous cell carcinoma of the head and neck varies worldwide. This study compared the outcomes of radiochemotherapy alone to surgery followed by radio(chemo)therapy (radiotherapy plus/minus concurrent chemotherapy). Patients and Methods: Data from 148 patients treated with radiochemotherapy alone were matched to 148 patients treated with surgery plus radio(chemo)therapy. Groups were matched 1:1 for nine potential prognostic factors including age, gender, performance status, tumor site, histologic grade, T category, N category, AJCC stage, and hemoglobin level before radiotherapy, and compared for locoregional control, metastases-free survival, and overall survival. Results: Locoregional control rates at 1, 2, and 3 years were 81%, 73%, and 67% after surgery plus radio(chemo)therapy and 81%, 74%, and 65% after radiochemotherapy alone (p = 0.89). Metastases-free survival rates were 86%, 80%, and 75% after surgery plus radio(chemotherapy) versus 87%, 80%, and 72% after radiochemotherapy alone (p = 0.57). Overall survival rates were 80%, 64%, and 63% after surgery plus radio(chemo)therapy versus 83%, 68%, and 60% after radiochemotherapy alone (p = 0.96). On multivariate analyses, T category (p < 0.001), N category (p = 0.004), and hemoglobin level prior to radiotherapy (p < 0.001) were associated with locoregional control. Histologic grade (p = 0.045), T category (p < 0.001), N category (p = 0.003), and hemoglobin level prior to radiotherapy (p < 0.001) were associated with metastases-free survival. Histologic grade (p = 0.030), ECOG performance status (p = 0.033), T category (p = 0.007), N category (p = 0.024) and hemoglobin level before radiotherapy (p < 0.001) were associated with overall survival. Conclusion: Outcomes of radiochemotherapy alone appeared similar to those of surgery plus radio(chemo)therapy. Randomized trials comparing both treatments for different tumor sites are warranted.

KW - Head-and-neck cancer

KW - Radiochemotherapy

KW - Surgery

UR - http://www.scopus.com/inward/record.url?scp=80755163551&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80755163551&partnerID=8YFLogxK

U2 - 10.1007/s00066-011-2262-2

DO - 10.1007/s00066-011-2262-2

M3 - Article

VL - 187

SP - 541

EP - 547

JO - Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]

JF - Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]

SN - 0179-7158

IS - 9

ER -